A cocktail of MAP assays for the common 15/18 bp deletions, together with a Bi-PAP-A assay for the common L858R mutation, could detect about 70–80% of EGFR mutations constituting about 10% of total lung cancers [10], [36]. This evidence concerns the gene EGFR and lung cancer.